Gout Resource Center

Gout is a common form of inflammatory arthritis, affecting ~9.2 million adults (3.9%) in the U.S. The good news: The etiology of gout is well understood, and effective, inexpensive medications exist to treat it. However, gaps in quality of care persist. Below, explore selected content from The Rheumatologist’s collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout. New features are added often, so check back frequently.

Gout expert Lisa Stamp, MBChB, FRACP, PhD, sorted through the 60+ research abstracts on gout accepted for presentation at ACR Convergence 2022 to bring you the most important concepts and findings.

FEATURED ARTICLE: Gout Research from ACR Convergence 2022 at a Glance

Reducing Immunogenicity of Pegloticase ... Click here to view abstract video

Reducing Immunogenicity of Pegloticase ... Click here to view visual abstract summary

Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi

Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often… [Read More]

Study: Pegloticase & Methotrexate Co-Treatment Helps Uncontrolled Gout

A larger proportion of patients with gout had a therapeutic response at six months when treated with methotrexate and pegloticase than with pegloticase alone, according to results from the multi-center, open-label MIRROR (methotrexate to increase response rates in patients with uncontrolled gout receiving KRYSTEXXA) study, recently published in the Journal of Rheumatology.1 The MIRROR study… [Read More]

Pegloticase Proves Promising for Gout in Patients who Have Undergone Kidney Transplant

Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.... [Read More]

Colchicine: An Ancient Drug with Modern Uses

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550… [Read More]

Case Report: Does a Young Woman with Gitelman Syndrome Have Gout?

Gout is the most common type of inflammatory arthritis in adults, and it typically occurs in men over the age of 50. When gout presents in younger patients or in women, this should warrant consideration of secondary causes. We describe an unusual genetic cause of tophaceous gout in a young, premenopausal woman. Case Report In… [Read More]

The ACR Releases a New Gout Guideline

In May, the ACR released a new treatment guideline for the management of gout for simultaneous publication in Arthritis & Rheumatology and Arthritis Care & Research.1 Based on evidence from more than 130 published studies, the guideline makes a total of 42 recommendations—of which 16 are strong: It has 27 recommendations for urate-lowering therapy (ULT)… [Read More]

New Study Identifies How Big a Role Diet Plays in Hyperuricemia

Living like a king has its price. And while kings and queens are primarily something of yesteryear, the vast majority of those living in reasonably wealthy nations can now live like kings. Now, back to that price. Gout, once known as the disease of kings, has been around at least since the time of the… [Read More]

Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

Patients with uncontrolled gout may benefit from a combination of pegloticase and methotrexate therapy, according to a small, retrospective study…... [Read More]

Clinical Insights into Gout Management: Rheumatology Drugs at a Glance Pt. 4

Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.... [Read More]